Please login to the form below
Wilson's disease
This page shows the latest Wilson's disease news and features for those working in and with pharma, biotech and healthcare.
AZ’s new rare disease unit wins in Wilson disease
AstraZeneca’s new rare disease unit, formed through the $39bn purchase of Alexion Pharmaceuticals, had announced positive results from a phase 3 trial in Wilson disease. ... Wilson disease is a rare, progressive genetic condition in which the body’s
Latest news
-
Pfizer buys dwarfism drug company Therachon for $810m
The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM) ... TA-46 will add to other pipeline candidates
-
Alexion adds to pipeline with $1.2bn Syntimmune buy
Alexion used a priority review voucher from an earlier rare disease therapy approval to accelerate the FDA’s deliberations and bring forward a possible approval date. ... $855m, adding orally-active copper binder WTX-101 in phase 3 testing for genetic
-
Alexion adds to pipeline rebuild with $855m Wilson buy
Also acquires the Swedish group’s lead product for Wilson’s disease. Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a ... Sweden-based Wilson’s lead product is WTX101, currently in phase III development
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- EU to revise pharmaceuticals law amid antibiotic shortages
- Medical Affairs: centre-stage in scientific engagement strategies
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
Cuttsy + Cuttsy
Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
